INBS — Intelligent Bio Solutions Cashflow Statement
0.000.00%
- $5.27m
- $1.06m
- $4.22m
Annual cashflow statement for Intelligent Bio Solutions, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.33 | -10.7 | -10.2 | -10.6 | -12.5 |
| Depreciation | |||||
| Non-Cash Items | 2.54 | 2.39 | 0.347 | 0.678 | 0.603 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.44 | 0.079 | -0.702 | -0.721 | -1.23 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.36 | -7.38 | -9.57 | -9.68 | -11.9 |
| Capital Expenditures | — | — | -0.005 | -0.232 | -0.126 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.88 | -0.694 | -0.216 | — | 0.04 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.88 | -0.694 | -0.221 | -0.232 | -0.086 |
| Financing Cash Flow Items | 0 | -1.33 | 9.12 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0 | 1.44 | 14.6 | 4.6 | 15 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.34 | -6.7 | 4.77 | -5.28 | 2.97 |